Amani Therapeutics

Amani Therapeutics is a biotechnology company focused on developing highly selective small molecule inhibitors for historically "undruggable" oncogenic targets. The company's primary focus is on the KRAS G12D mutation, a prevalent driver in various hard-to-treat malignancies such as pancreatic, colorectal, and lung cancers. By utilizing a proprietary structure-based drug design platform, Amani aims to create best-in-class therapies that overcome the limitations of first-generation inhibitors. The company is based in South San Francisco and is led by a team with extensive experience in oncology drug discovery and development. Amani's approach involves targeting specific conformational states of the KRAS protein to achieve superior potency and selectivity.